Lineham, Ella, Spencer, John and Morley, Simon (2017) Dual abrogation of Mnk and mTOR; a novel therapeutic approach for the treatment of aggressive cancers. Future Medicinal Chemistry, 9 (13). ISSN 1756-8919

PDF - Published Version Available under License Creative Commons Attribution-NonCommercial No Derivatives. Download (1MB)

Abstract

Targeting the translational machinery has emerged as a promising therapeutic option for cancer treatment. Cancer cells require elevated protein synthesis for cell growth and exhibit augmented activity to meet the increased metabolic demand. Eukaryotic translation initiation factor 4E (eIF4E) is necessary for mRNA translation, its availability and phosphorylation are regulated by the PI3K/AKT/mTOR and Mnk1/2 pathways, respectively. The phosphorylated form of eIF4E drives the expression of oncogenic proteins including those involved in metastasis. This article will review the role of eIF4E in cancer, its regulation, and discuss the benefit of dual-inhibition of upstream pathways. The discernible interplay between the Mnk1/2 and mTOR signaling pathways provides a novel therapeutic opportunity to target aggressive migratory cancers through the development of hybrid molecules.

Item Type:	Article
Schools and Departments:	School of Life Sciences > Biochemistry
Depositing User:	Ella Lineham
Date Deposited:	02 Jun 2017 08:57
Last Modified:	02 Jul 2019 17:31
URI:	http://sro.sussex.ac.uk/id/eprint/68305

View download statistics for this item

📧 Request an update